Evidence map›Paper›PMID 30347802›Full record

ReviewPharmaceuticals (Basel, Switzerland)2018

Tuning the Anti(myco)bacterial Activity of 3-Hydroxy-4-pyridinone Chelators through Fluorophores.

Maria Rangel, Tânia Moniz, André M N Silva, Andreia Leite

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Iron as Therapeutic Target in Human Diseases.Pharmaceuticals (Basel, Switzerland) · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maria RangelREQUIMTE-LAQV, Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal. mcrangel@fc.up.pt.ORCID 0000-0002-0998-1437
Tânia MonizREQUIMTE-LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 40169-007 Porto, Portugal. tania.moniz@fc.up.pt.
André M N SilvaREQUIMTE-LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 40169-007 Porto, Portugal. andre.silva@fc.up.pt.ORCID 0000-0001-5554-7714
Andreia LeiteREQUIMTE-LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 40169-007 Porto, Portugal. acleite@fc.up.pt.
Universidade do Porto · PT

Funding

Fundação para a Ciência e a Tecnologia NORTE-07-0124-FEDER-000066; NORTE-01-0145-FEDER-000024; NORTE-07-0162-FEDER-000048 UID/QUI/50006/2013 and UID/QUI/50006/2013-POCI/01/0145/FEDER/007265; SFRH/BD/79874/2011.and SFRH/BPD/85793/2012
6 · The paper itself

Abstract

Controlling the sources of Fe available to pathogens is one of the possible strategies that can be successfully used by novel antibacterial drugs. We focused our interest on the design of chelators to address

Indexed as

3-hydroxy-4-pyridinoneantibacterial activitybacteriafluorescent iron chelatorfluorophoremembrane interactionsrhodamine

Identifiers

PMID30347802
PMCPMC6316862
OpenAlexW2897366822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.